GRAIL, Inc.

GRAL Healthcare Diagnostics & Research

GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.

Revenue
+3.71%
EPS
+10.2%
Free cash flow
−24.9%

Quarter to September 2026, against a year earlier

120.97 1.84 +1.54%
Market cap
$5.3B
P/E
0.0×
Fwd P/E
−14.5×
Dividend yield
—
F-score
6/9
Altman Z
0.37
Beneish M
n/a
Dividend safety
n/a

GRAIL, Inc. (GRAL) Price to free cash flow

Alert me on Price to free cash flow

GRAIL, Inc. has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —

Quarterly newest first

Period Price to free cash flow Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
9 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

Price to free cash flow against peers

Company Price to free cash flow
GRAL GRAIL, Inc. n/m
ADPT Adaptive Biotechnologies Corporation compare n/m
VCYT Veracyte, Inc. compare 12.0×
ICLR ICON PLC compare 18.1×
QGEN QIAGEN N.V. compare 23.8×
SHC Sotera Health Company compare 33.5×
CDNA CareDx, Inc. compare 68.9×
BLLN BillionToOne, Inc. compare 156×
RDNT RadNet, Inc. compare 189×
Diagnostics & Research industry median 33.5×
Healthcare sector median 21.1×
Market median 14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on GRAL